{
    "Trade/Device Name(s)": [
        "Cholesterol"
    ],
    "Submitter Information": "Randox Laboratories Limited",
    "510(k) Number": "K150654",
    "Predicate Device Reference 510(k) Number(s)": [
        "K923504"
    ],
    "Regulatory Class": "Class I",
    "Product Code(s)": [
        "CHH"
    ],
    "Summary Letter Date": "September 21, 2015",
    "Summary Letter Received Date": "September 24, 2015",
    "Submission Date": "September 29, 2015",
    "Regulation Number(s)": [
        "21 CFR 862.1175"
    ],
    "Regulation Name(s)": [
        "Cholesterol (total) test system"
    ],
    "Analyte Class(es)": [
        "chemistry"
    ],
    "Analyte(s)": [
        "Cholesterol"
    ],
    "Specimen Type(s)": [
        "Serum",
        "Plasma (Lithium Heparin)",
        "Plasma (K2 EDTA)"
    ],
    "Specimen Container(s)": [],
    "Instrument(s)/Platform(s)": [
        "RX Daytona Plus"
    ],
    "Method(s)/Technology(ies)": [
        "Enzymatic endpoint method"
    ],
    "Methodologies": [],
    "Submission Type(s)": [
        "Assay",
        "Reagent"
    ],
    "Document Summary": "FDA 510(k) summary for Randox Cholesterol enzymatic assay for quantitative determination of cholesterol in serum and plasma on RX Daytona Plus analyzer.",
    "Indications for Use Summary": "For quantitative in vitro determination of cholesterol in serum and plasma to aid diagnosis and treatment of blood cholesterol and lipid metabolism disorders.",
    "fda_folder": "Clinical Chemistry"
}